Pound-ing The Table With Eloralintide-Tirzepatide Combo

研报英文原文证据摘录

Pound-ing The Table With Eloralintide-Tirzepatide Combo

July 1, 2026

Limited safety detail disclosed, with GI the most common side effects. Across both studies, the eloralintide

+tirzepatide combination arms showed higher rates of TEAEs than either monotherapy comparator (tirzepatide+placebo

or eloralintide+placebo), which is broadly consistent with an additive-efficacy profile. GI events were the most common

TEAEs as expected, though the vast majority were characterized as mild to moderate in severity. No specific rates

or serious adverse event figures were explicitly provided, though we'd note that the divergence between number of

participants "with valid observations" to the number of patients at baseline within each arm point to patient dropout

rates. On the Study A eloralintide 9 mg + tirzepatide 15 mg arm, for example, only 3 patients had valid observation from

the original 12 randomized. And in the Study B eloralintide 9 mg + tirzepatide 15 mg, 12 out of the 16 patients were

evaluable for efficacy. Here, we'd highlight again that this phase 1b trial was intended to be proof of concept, and the

ongoing phase 2 study (more on this below) should help ameliorate these discontinuations through optimized dosing

and titration, in our view.

Next steps. Recall, at ADA, LLY highlighted tirzepatide as one of the company's biggest clinical development programs.

At the moment, we'd point to just five ongoing phase 3 trials, but clearly LLY has high aspirations. With regard to the

readout for the phase 2 combination trial (PCD 6/2026), mgmt. has told us that a standalone press release is not to be

expected, consistent with the company's typical disclosure approach, but we should expect results at a medical meeting

in the 2H26.

Please help us protect your advantage...